INTRODUCTION

Top Abstract Introduction Materials & Methods Results Discussion References

A variety of animal DNA and RNA viruses can establish long-term persistent infections. For a cytolytic virus to institute a persistent infection in its host cells, more harmonious interactions between virus and cell must first occur to restrict the virus-induced cytopathic effects (CPE). This persistent status can be achieved by virus infection of nonpermissive cells or of cells under a nonpermissive environment; alternatively, emergence of virus and/or cell variants during the infection course appears to also contribute to persistence (3). True latent infections, which do not yield infectious virions, are commonly associated with DNA viruses when nonpermissive cells are infected; the virus may resume replication as long as the condition remains appropriate. On the other hand, the lack of susceptibility of target cells to virus infection often leads to an abortive replication of RNA viruses. Most RNA viruses can only persist in infected cells where at minimum a reduced level of virus replication is still able to take place, thereby resulting in constant shedding of moderate amounts of infectious virions.

Characteristically, most animal DNA viruses seem to merely play a passive role either in the establishment of latency or in viral reactivation (reviewed in reference 3). In contrast, both viruses and their infected host cells have been shown to actively participate in the establishment of persistence for several RNA viruses, namely reovirus (2), Sindbis virus (25), poliovirus (1, 54), and coxsackie A9 virus (50). Among these viruses, mutations in certain viral genes have been demonstrated to be responsible for turning a lytic infection into a persistent one (reviewed in reference 3). Still, the involvement of cellular genes in viral persistence remains largely unexplored.

Human bcl-2 was the first cellular gene recognized to be capable of blocking apoptosis induced by certain RNA viruses (21, 26, 27, 39, 51). Studies involving Sindbis virus (26), Semiliki Forest virus (44), and influenza virus (21, 38) have further indicated that constitutive bcl-2 expression can not only prevent the infected cells from undergoing apoptosis but also, subsequently, render the cells to be persistently infected. These results suggest that bcl-2 may play a role in determining whether a cytolytic RNA virus can chronically infect its host cells.

Like other mosquito-borne flaviviruses, Japanese encephalitis virus (JEV) is transmitted to humans through persistently infected mosquito vectors. JEV infection is especially prevalent in some East Asian countries and may cause an acute encephalitis in humans which is frequently associated with a high mortality rate (6, 52, 53). The genome of JEV is a single-stranded, positive-sense RNA of approximately 11 kb in length which contains an open reading frame encoding a single polyprotein. In the infected cells this viral polyprotein is proteolytically cleaved into at least 11 proteins. The virus structural proteins, including the capsid (C), membrane (M; precursor M, prM), and envelope (E) proteins, are encoded by the 5' one-third of the open reading frame, and the nonstructural (NS) proteins, designated NS1 through NS5, are encoded in the remainder (reviewed in references 10 and 42). Among these proteins, prM, E, and NS1 are membrane-associated glycoproteins. With two N-linked glycosylation sites at amino acid positions 130 and 207, the actual molecular size of NS1 detected in JEV-infected cells is approximately 46 kDa. The proteolytic cleavage between E-NS1 ensues the translocation of NS1 into the lumen of the endoplasmic reticulum (ER), and the cleavage between NS1-2A might occur in the lumen of the vesicular compartments (10). JEV is unique among flaviviruses in that an additional NS1-2A-related protein (named NS1') with a molecular size of about 53 kDa is often observed in the JEV-infected cells (10) and is probably generated by an unknown protease that recognizes an alternative cleavage site within NS2A (32). The biological significance for the existence of both types of NS1 proteins in JEV-infected cells remains unclear.

The natural life cycle of JEV involves complex relationships among arthropods, vertebrate reservoirs, and humans, illustrating the uniqueness of the broad host spectrum for JEV infection (9). In fact, a wide variety of primary and continuous cell cultures from different origins (e.g., monkey, hamster, pig, chicken, and mosquito) can support the productive growth of JEV. JEV is usually cytolytic for susceptible cells, so due to apparent CPE induced by JEV infection, Vero, LLC-MK2 (monkey kidney cells), and BHK-21 (baby hamster kidney cells) are frequently used for virus titration by plaque assays (49). Nevertheless, persistent JEV infection has been demonstrated in cell cultures (11, 45-47), as well as in a mouse model (33, 34). In humans, latent infection of mononuclear cells in the peripheral blood from JEV-infected patients has also been documented (48); moreover, viral persistence in the human nervous system has been shown in approximately 5% of JEV-associated encephalitis cases (41), suggesting that JEV persistence might contribute to neural sequelae after the acute infection phase. One proposed mechanism for other flaviviruses to persist in cell cultures is the production of defective interfering (DI) particles (5, 23, 40, 45). However, the emergence of DI virus during long-term infections has not been universally observed.

The underlying mechanism for JEV persistence in vitro and in vivo is not fully understood. We previously demonstrated that, despite the fact that JEV could be an apoptotic inducer (27), persistent infection of JEV could also be established in different cell types after a primary lytic infection and that such persistence was closely associated with the abnormal expression of truncated JEV NS1 proteins (11). Still, JEV persistence has never been successfully established in BHK-21 and CHO cells, although both of them could support the productive replication of JEV, indicating that it was the cell type difference, rather than the permissiveness, of target cells that determined the achievement of JEV persistence. The present study demonstrates that expression of human bcl-2, which delays JEV-induced apoptosis, can assist in instituting JEV persistence in BHK-21 and CHO cells after the lytic phase of infection. Moreover, we provide evidence to show that for the development of an environment suited to JEV persistence, bcl-2 appears to exert its antiapoptotic, but not antiviral, function to subvert JEV CPE. Thus, bcl-2 becomes the first cellular gene shown to be capable of modulating the outcome of JEV infection in a cultured system.

	MATERIALS AND METHODS

Top Abstract Introduction Materials & Methods Results Discussion References

Viruses and cell lines. The Taiwanese local JEV strain RP-9, a plaque-purified strain (11, 12), was employed throughout this study. The propagation of virus was carried out in BHK-21 and CHO cells with RPMI 1640 medium containing 2% fetal calf serum (FCS). Virus titers were determined by plaque-forming assay on BHK-21 cells.

Virus infection and titration. To infect with JEV, monolayers of the indicated cell lines grown in 6- or 12-well plates were initially adsorbed with JEV at a multiplicity of infection (MOI) of 5 for 1 h at 37°C. After adsorption, the unbound viruses were removed by three gentle washings with serum-free RPMI 1640 medium. Fresh medium containing 2% FCS was added to each plate for further incubation at 37°C. At the end of infection, the culture media were harvested for plaque-forming assay to determine virus titers. Briefly, virus dilution was added onto 80% confluent BHK-21 cells and incubated at 37°C for 1 h. After adsorption, the cells were washed and overlaid with 1% agarose (SeaPlaque; FMC BioProducts) containing RPMI 1640 with 1% FCS. After incubation for 4 days, the resulting cells were fixed with 10% formaldehyde and stained with 0.5% crystal violet for plaque counting. Virus titers were denoted as PFU per milliliter.

Infectious center assay. To determine the exact portion of a cell population capable of producing infectious virus particles, an infectious center assay was carried out. Briefly, persistent cell clones were trypsinized and washed three times with serum-free RPMI 1640 medium to make single-cell suspensions. Cell suspensions were counted, serially diluted with medium, mixed with target BHK-21 cell suspensions, and plated into 96-well microtiter plates. After incubation at 37°C for 4 h, the adherent cells were washed and overlaid with 1% agarose (SeaPlaque) containing RPMI 1640 with 1% FCS for virus titration as described above.

Viral one-step growth curve. BHK-21 and its derivatives (2 × 10⁶) were infected with viruses at an MOI of 5. After 1 h of adsorption at 37°C, the unbound virus particles were removed from cells by three washes with phosphate-buffered saline (PBS). The infected cells were then grown in RPMI 1640 medium supplemented with 2% FCS at 37°C. At the indicated time points postinfection, the culture supernatants of infected cells were collected and clarified by centrifugation. Next, the virus titers in supernatants were determined by plaque assay on BHK-21 cells.

Monoclonal antibodies. The specificity of monoclonal antibodies D2/39.1 and JE7/45-2 against JEV NS1 used in this study was confirmed by Western blotting and immunoprecipitation by using the antigen source as previously described (11). In addition to recognizing native forms of NS1, both antibodies can detect denatured forms of NS1 when the lysate is boiled in the presence of 2-mercaptoethanol prior to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), indicating that the two antibodies recognize a linear epitope of NS1. As characterized with several NS1 deletion mutants expressed in BHK-21 cell (11), the epitope location recognized by D2/39.1 is located in the N-terminal one-third of NS1. By using synthetic peptides for fine mapping, the epitope of D2/39.1 was further mapped to a 16-mer peptide whose sequence was TELRYSWKTWGKAKM; this peptide contained a consensus linear sequence [WK(A/T)WGK] present in the NS1 of JEV, Kunjin virus, and dengue viruses (16, 17).

Cloning of persistently infected cells. Limiting dilution was used to clone persistently infected cells as previously described (11). Briefly, the bulk of persistently JEV-infected B2-5 cells were trypsinized and washed once with complete RPMI 1640 medium. Cell suspensions were counted, diluted with medium, and distributed into a 96-well microtiter plate. Each well, which contained an average of a single cell, was microscopically observed daily for the presence of cell colonies. Once they became confluent in wells, cells were treated with trypsin and transferred to new tissue culture flasks for further growth.

Indirect immunofluorescence assay (IFA) staining. Cells were fixed in acetone-methanol (1:1) solution for 5 min and stained with JEV-specific monoclonal antibodies at room temperature for 1 h. The dilutions of antibodies used in this assay were 1:500 or 1:1,000. After being washed with PBS, the cells were reacted with goat anti-mouse fluorescein-conjugated secondary antibody (Cappel) and examined with a Leitz fluorescent microscope.

Cell labeling and immunoprecipitation. Cell monolayers were starved with methionine-free and cysteine-free RPMI 1640 for 1 h and labeled with 50 µCi of ³⁵S-labeled Pro-Mix (Amersham) per 35-mm dish for 2 h at 37°C. The cells were rinsed and lysed with lysis buffer (1% Nonidet P-40; 150 mM NaCl; 50 mM Tris-HCl, pH 7.5; 1 mM EDTA) containing a cocktail of protease inhibitors, including 20 µg of phenylmethylsulfonyl fluoride, 2 µg of leupeptin, and 2 µg of aprotinin per ml. Aliquots of cell lysates were mixed with monoclonal antibodies captured on staphylococcal protein A-coated Sepharose (Pharmacia) for 1 h at room temperature. The immune complexes were washed with radioimmunoprecipitation assay buffer (10 mM Tris-HCl, pH 7.5; 150 mM NaCl; 5 mM EDTA; 0.1% SDS; 1% Triton X-100; 1% sodium deoxycholate), analyzed by SDS-10% PAGE, and fluorographed at 70°C. For endoglycosidase F (endo-F) digestion, the immunoprecipitated proteins were boiled in endo-F boiling buffer (50 mM sodium phosphate, pH 7.5; 0.5% SDS; 1% 2-mercaptoethanol) and then incubated overnight at 37°C with an equal volume of the endo-F incubation buffer (50 mM sodium phosphate, pH 7.5; 2% Nonidet P-40; 0.2% SDS; 1% 2-mercaptoethanol; 25 mM EDTA) with or without endo-F (Boehringer Mannheim).

Western immunoblot analysis. Cell monolayers were rinsed and lysed with lysis buffer as described above. Cell lysates were mixed with an equal volume of sample buffer (without -mercaptoethanol), boiled or not boiled, separated by SDS-PAGE, and transferred to nitrocellulose membranes (Hybond-C Super; Amersham). The nonspecific antibody-binding sites were blocked with 5% skimmed milk in PBS and reacted with monoclonal anti-JEV E, NS1, or NS3 antibodies (11). The blots were then treated with horseradish peroxidase-conjugated goat anti-mouse immunoglobulin (Cappel) and developed with an ECL system (Amersham).

RNA preparation and reverse transcriptase (RT)-PCR reaction. Total RNA of the JEV-infected cell cultures or viral RNA harvested from the media were incubated with lysis buffer (4 M guanidine thiocyanate; 50 mM Tris HCl, pH 8.5; 10 mM EDTA; 0.5% sarcosyl) for 15 min at 4°C and extracted twice with an equal volume of acid phenol-chloroform (14, 28). RNA in the aqueous phase was precipitated with isopropanol. Four different primers were used in the amplification reaction, including primers a (5'-GCGGATCCAGACACTGGATGTGCCA-3', "+" sense, nucleotides [nt] 2478 to 2493), b (5'-GCGGATCCTAAGCATCAACCTGTGA-3', "" sense, nt 3534 to 3519), c (5'-GGAAGGGGAGACAAAGCAGATCAACC-3', "+" sense, nt 2133 to 2157), and d (5'-CTAGTGACAGATCTGACTCC-3', "" sense, nt 2662 to 2643). Primers a and b were used to amplify the full length of NS1, and primers c and d were used to amplify the junction between E and NS1. When primer b or d was used, 5 µg of purified RNA was transcribed into first-strand cDNA at 42°C for 1 h in 20 µl of reaction buffer containing 200 U of Moloney murine leukemia virus RT (Bethesda Research Laboratories), 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl₂, 10 mM dithiothreitol, and 1 mM concentrations of dATP, dGTP, dCTP, and dTTP. When primer set a and b or primer set c and d was used, 2 µl of the resulting first-strand cDNA sample were PCR amplified in 100 µl of reaction mixture containing 5 U of Taq polymerase (Perkin-Elmer); 2 mM MgCl₂; 1 mM concentrations of dATP, dGTP, dCTP, and dTTP; 20 mM Tris-HCl (pH 8.4); and 50 mM KCl. Thirty-five cycles of amplification were performed with a PCR thermocycler (AG 9600 Thermal Station; AcuGen System). Each cycle consisted of a denaturation step at 94°C for 30 s followed by a primer-annealing step at 55°C for 30 s and a primer extension step at 72°C for 30 s, except for a longer denaturation step (5 min) and a longer primer extension step (10 min) at the first and last cycle.

Construction of plasmid expressing full-length or truncated NS1 proteins. Plasmid pJNS1, expressing full-length NS1 protein, has been described previously (29). To construct a truncated NS1, pJNS1 was used as a template to perform a PCR cloning. The primers used for PCR were 5'-GCATTCTCTTTGCCCCGGAATTGGC-3' (+ sense, located at nt 2839 to 2863 in the NS1 region) and 5'-GCGGATCCTAAGCATCAACCTGTGA-3' ( sense, complementary to nt 3519 to 3534 in the NS1 region and also containing the underlined sequence with an extra BamHI site that was convenient for further subcloning). The PCR products were first TA cloned into a vector pCR3.1 (Invitrogen) and, after BamHI digestion, the properly oriented insert was released and then subcloned into expression vector pSecTag-B (Invitrogen). The resulting plasmid was able to express a truncated NS1 with an arbitrary deletion of the first 120 amino acids, and the N-terminus of this truncated NS1 protein was fused in-frame with a signal sequence derived from mouse immunoglobulin  chain, which could direct the engineered proteins into the ER during the translation process.

Establishment of cell clones permanently expressing Bcl-2 or Bcl-X_L. All cell lines stably expressing Bcl-2 or Bcl-X_L were cloned from single cells by the limiting-dilution method described above. BHK-21 cells permanently expressing human Bcl-2 (B2-5) were as described previously (27). To establish CHO cells stably expressing bcl-2, cells were transfected by lipofectamine (BRL) with human bcl-2 expression plasmid pZipBcl-2 or with a vector control, pZipneo (26). The transfected cells were selected and cloned in the presence of Geneticin (GIBCO). The expression of bcl-2 in cell clones was assessed by Western blotting and IFA by using an antibody specific for the human Bcl-2 protein (Santa Cruz). The resultants were cultured in RPMI 1640 medium containing 5% FCS. Similarly, bcl-X_L/pCR3.1 was used to construct BHK-21 cells constitutively expressing human Bcl-X_L proteins.

	RESULTS

Top Abstract Introduction Materials & Methods Results Discussion References

Establishment of JEV persistence in the cells stably expressing bcl-2. Previously, we demonstrated that following the initial lytic infection, JEV persistence could be readily established in mouse neuroblastoma N18, Vero, mouse astrocytoma DBT, and human neuronal progenitor NT2 cells (11). In contrast, this persistence was never successfully established in BHK-21 and CHO cells. By 3 days postinfection by JEV, both BHK-21 and CHO cells were completely killed through some mechanism, at least in part, involved in apoptosis (27 [also see below]). In addition, we observed that the constitutive expression of human bcl-2, a proto-oncogene, inhibited JEV-induced apoptosis in BHK-21 cells (27). In the present study, we therefore investigated whether JEV persistence could be instituted in the cells that stably expressed either bcl-2 or its antiapoptotic homolog, human bcl-X_L.

View larger version (46K): [in this window] [in a new window]   FIG. 1.   (A) Western blot analysis of the expression of human bcl-2 in permanent cell clones derived from BHK-21 cells. The 26-kDa Bcl-2 protein (as indicated by arrow) was expressed only in B2-5 and B3-1 cell clones but not in control BHK-21 cells. Numbers on the left are molecular masses in kilodaltons. (B) Western blot analysis of the expression of human bcl-XL in stable cell clones derived from BHK-21 cells. The 28-kDa Bcl-XL protein (as indicated by arrow) was observed in stable clones Bcl-XL#1 and #4 but not in controls of B2-5 or BHK/pCEP4 cells. (C) IFA staining of persistently JEV infected B2-5/RP9 cells with monoclonal antibodies specific for JEV NS1 protein.

View larger version (19K): [in this window] [in a new window]   FIG. 2.   (A) Effect of stable bcl-2 or bcl-XL expression on cell growth in response to JEV infection. Cells (106) were infected with JEV RP9 at an MOI of 10, and viable cells were assessed by trypan blue exclusion in three independent experiments at the indicated time intervals postinfection. (B) Growth curves of bcl-2-expressing and wild-type BHK-21 cells in the absence of JEV infection. Growth curves of the two cells were determined by their viability as in panel A at the indicated points after cells were seeded.

Effects of bcl-2 expression on JEV replication and spread. We next examined the mechanism by which bcl-2 enabled the cells to become persistently infected with JEV. As shown by a one-step growth curve of the virus, the overexpression of bcl-2 failed to suppress the virus replication in B2-5 cells infected with JEV. Both the virus growth curves and the virus yields from infection appeared to be comparable to those from a primary JEV infection in wild-type BHK-21 cells (27). To further study the effect of bcl-2 on JEV infection during multiple rounds of replication, wild-type BHK-21 and B2-5 cells were grown to confluence and then infected with RP9 at an MOI of 0.001. At 24 and 48 h postinfection, the cells were stained by immunofluorescent labeling with monoclonal antibodies specific for JEV to monitor infection status. As Fig. 3 shows, the JEV infection in B2-5 cells (top panels) could scatter around as readily as in the wild-type BHK-21 cells (bottom panels) at 48 h postinfection, as evidenced by nearly 100% of both infected cells showing positive IFA staining (right panels). These results illustrate that the bcl-2 expression did not restrict the spread of JEV in the cultured cells. Since bcl-2 expression did not influence JEV replication in a primary infection, these data thus suggest that Bcl-2 proteins may primarily play an antiapoptotic, rather than an antiviral, role that assists in the establishment of JEV persistence in B2-5 cells.

View larger version (129K): [in this window] [in a new window]   FIG. 3.   The effect of stable bcl-2 expression on multiple rounds of JEV infection in BHK-21 cells. The bcl-2-expressing cells (top panels) and wild-type BHK-21 cells (bottom panels) were infected with RP9 at a low MOI (0.001). At 24 or 48 h postinfection, the cells were fixed and stained by IFA with JEV-specific antibodies.

Examination of Bcl-2 cleavage products in Bcl-2-overexpressing cells either persistently or primarily infected with JEV. At the early phase of the persistence process, JEV infection killed more than 90% of the bcl-2-expressing cells (Fig. 2A), indicating that Bcl-2 could not completely protect the cells from virus-induced cell death. Hardwick and associates (13) demonstrated that conversion of Bcl-2 to a Bax-like death effector by caspases might occur in the systems where Bcl-2 failed to suppress apoptosis. By Western blot analysis with antibody against Bcl-2, we next sought to examine the Bcl-2 cleavage products in the CHO-bcl2 cells either primarily or persistently infected with JEV. As Fig. 4B indicates, when persistently infected by RP9, the CHO-bcl2 cells displayed no truncated Bcl-2 proteins (lane 3), whereas the primarily infected cells exhibited a cleaved species of Bcl-2 protein that was 23 kDa (lane 4); as a control, no cleavage product of Bcl-2 was detected in CHO-bcl2 cells in the absence of JEV infection (lane 2). These data suggest that there might be a Bcl-2 cleavage-resistant cell population being selected out from infected CHO-bcl2 cells during establishment of JEV persistence which was able to suppress virus-induced cell death.

View larger version (33K): [in this window] [in a new window]   FIG. 4.   (A) The truncated NS1 proteins derived from the persistently JEV-infected CHO cells expressing bcl-2. Cell lysates from the primary infection of CHO cells (lane 1) and from the persistent infection of CHO-bcl-2/RP9 (lane 2) and B2-5/RP9 cells (lanes 3) were separated by SDS-10% PAGE and immunoblotted with anti-NS1 monoclonal antibody JE7/45-2. The wild-type NS1 proteins are indicated by thin arrows, and the truncated ones (p39) are marked by a thick arrow. (B) Examination of Bcl-2 cleavage products in the CHO-bcl-2 cells either persistently or primarily infected with JEV. The cell lysates from CHO-bcl-2 alone (lane 2) and from CHO-bcl-2 either persistently (lane 3) or primarily (lane 4) (at 24 h postinfection) infected by RP9 were immunoblotted with anti-Bcl-2 antibody 100 (Santa Cruz). The wild-type Bcl-2 is indicated by a thin arrow, and its cleavage product is marked by a thick arrow, along with Bcl-2.

Characterization of the truncated NS1 proteins from JEV persistent cell lines. To study the expression profiles of viral proteins, [³⁵S]methionine-labeled cell lysates from primarily infected BHK-21 cells and from JEV-persistent cell clones were precipitated by JEV-specific antibodies and separated by SDS-PAGE (Fig. 5). When monoclonal antibodies specific for either E (Fig. 5, lanes 1 to 5) or NS3 (Fig. 5, lanes 11 to 15) were used, the expression patterns were comparable between primary and persistent JEV infections, although the amounts of viral proteins varied. In contrast, as monoclonal antibodies against JEV NS1 (Fig. 5, lanes 6 to 10) were used, in addition to normal NS1 and NS1' proteins, other protein bands with faster mobilities were observed in the persistently infected clones B1-1/RP9 (lane 8), B1-3/RP9 (lane 9), and B2-6/RP9 (lane 10), but not in the primarily infected BHK-21 cells (lanes 6).

View larger version (44K): [in this window] [in a new window]   FIG. 5.   Profiles of viral protein expression between primary and persistent JEV infections. [35S]methionine-labeled lysates from the JEV-infected cells were immunoprecipitated with monoclonal antibodies specific for E (E, lanes 1 to 5), NS1 (NS1, lanes 6 to 10), or NS3 (NS3, lanes 11 to 15). Results from primary infection of BHK-21 cells with RP9 are shown in lanes 1, 6, and 11; results from persistent clones are in lanes 3 to 5, 8 to 10, and 13 to 15. The positions of each viral protein as determined by SDS-10% PAGE are indicated by arrows. Note that additional protein bands, marked by an asterisk, were found only in the cell lysates from JEV-persistent clones when precipitated by anti-NS1 monoclonal antibody (lanes 8 to 10).

View larger version (49K): [in this window] [in a new window]   FIG. 6.   (A) Immunoblot analysis of NS1 and its derivatives from primary or persistent JEV infections. Cell lysates from primary infection of BHK-21 cells (lanes 1 and 4) and from persistent infection of B2-5/RP9 (lanes 2 and 5) and C2-2 cells (lanes 3 and 6) were separated by SDS-10% PAGE and immunoblotted with anti-NS1 monoclonal antibody JE7/45-2. Protein samples were treated either with boiling (lanes 4 to 6) or without boiling (lanes 1 to 3). The wild-type NS1 proteins are indicated by arrows. The truncated NS1 and NS1' are marked by asterisks. Molecular mass markers (kilodaltons) are on the left of the figure. (B) Glycosylation analysis of NS1 proteins by endo-F digestion. Cell lysates from JEV primary infection of BHK-21 (lanes 1 and 4) and from persistent infection of B2-5/RP9 (lanes 2 and 5) and C2-2 cells (lanes 3 and 6) were immunoprecipitated by anti-NS1 monoclonal antibodies and then were treated either without (lanes 1 to 3) or with (lanes 4 to 6) endo-F at 37°C for 16 h. The deglycosylated NS1 and NS1', as well as their truncated proteins p45 and p39 (lanes 4 to 6), are indicated by open triangles; their counterparts without endo-F digestion (lanes 1 to 3) are marked by arrows. (C) Localization of the truncation region to the N termini of NS1 and NS1' proteins derived from the persistently JEV-infected cells by immunoprecipitation with anti-NS1 monoclonal antibodies. 35S-labeled lysates from primarily infected BHK-21 (lanes 1 and 4) and persistently infected B2-1/RP9 (lanes 2 and 5) and B2-5/RP9 (lanes 3 and 6) cells were precipitated by anti-NS1 D2/39.1 (lanes 1 to 3) or JE7/45-2 (lanes 4 to 6) and then separated by SDS-10% PAGE. The wild-type NS1 and NS1' are marked with arrows, and the truncated protein p39 is marked by an asterisk. Note that only antibody JE7/45-2 recognized the truncated NS1 (lanes 5 and 6).

View larger version (47K): [in this window] [in a new window]   FIG. 7.   Construction of the truncated NS1 in expression vector pSecTag. (A) Full length of the amino acid sequence for JEV NS1 protein. The boxed amino acids are the sequence recognized by monoclonal antibody D2/39.1, as described in Materials and Methods. Amino acids underlined and marked with an asterisk are the predicted sequences for glycosylation. The truncated NS1, marked with an arrow at the start position 121, was created by artificial deletion of the first 120 amino acids of NS1 and PCR cloned into expression vector pSecTag (Invitrogen). (B) Expression of the truncated NS1 protein from plasmid t-NS1, indicated by an arrow, was confirmed by an in vitro coupled transcription-translation assay (TNT; Promega). (C) Expression of truncated NS1 proteins in a stable cell line, T1. Plasmid t-NS1 was used to transfect BHK-21 cells to establish a permanent cell line (T1) stably expressing truncated NS1. Cell lysates from B2-5/RP9 cells (lanes 1 and 4), primarily infected BHK-21 cells (lane 2), and T1 cells (lanes 3 and 5) treated with (lanes 4 and 5) or without (lanes 1 to 3) heat denaturation were immunoblotted with anti-NS1 JE7/45-2.

Effects of overexpression of truncated NS1 on JEV persistence. Truncated NS1 proteins have been demonstrated to be strongly associated with JEV persistence in the present (Fig. 4 to 6) and earlier (11) studies. To further determine whether the generation of truncated NS1 proteins is a cause for or an effect of JEV persistence in cell cultures, we performed experiments to determine how a stable expression of truncated JEV NS1 might influence JEV persistence in BHK-21 cells. The truncated NS1, obtained by arbitrary deletion of amino acids 1 to 120 from the N terminus of JEV NS1 (Fig. 7A), was cloned into the expression vector pSecTag under the control of the T7 and CMV promoters, and the plasmid t-NS1 resulted. Once confirmed by in vitro expression for NS1 (Fig. 7B), plasmid t-NS1 was used to establish stable cell lines that constitutively expressed truncated NS1. Representative cell clone T1 is shown in Fig. 7C, in which truncated NS1 expressed in the cell lysates could be detected by immunoblotting (lanes 3 and 5). Without heat denaturing, truncated NS1 from T1 cells appeared to form dimers in the absence of the N terminus of normal NS1 (Fig. 7C, lane 3). The distribution of truncated NS1 in T1 cells was primarily cytoplasmic (data not shown), resembling that of normal NS1 proteins in JEV-infected cells. Endo-F digestion analysis showed that the truncated NS1 proteins expressed from T1 cells were properly glycosylated in the ER (data not shown). Moreover, the amount of truncated NS1 expressed from T1 cells appeared to be comparable to that from JEV-persistent clone B2-5/RP9 cells (data not shown). Following a primary infection by JEV, T1 cells were all killed by 4 days postinfection; this survival pattern was similar to that of infected wild-type BHK-21 cells by the second day postinfection, whereas the positive control B2-5 cells exhibited a slow killing kinetic in response to JEV infection and, as a result, JEV persistence was eventually established in B2-5 cells during long-term culture. Moreover, the one-step growth curves of JEV were found to be comparable among T1, B2-5, and BHK-21 cells (data not shown), indicating that the expression of truncated JEV NS1 alone did not affect JEV replication. Taken together, these results imply that truncated NS1 was probably not a cause for, but was instead a consequence of, the establishment of JEV persistence in cell cultures.

	DISCUSSION

Top Abstract Introduction Materials & Methods Results Discussion References

In this study we demonstrated that the constitutive expression of human bcl-2 allowed JEV persistence to be established in the BHK-21 and CHO cells that were originally unbearable to such a chronic infection. At the initial stage of persistence, JEV killed virtually 90% of the infected cells (Fig. 2A), even though they were actually expressing bcl-2 (Fig. 1A). This finding indicated that conversion from a lytic infection to a persistent infection must be under tremendous selection pressures for both virus and host cells. By contrast, for the persistence of Sindbis and Semliki Forest viruses to be established, bcl-2 expression seemed to protect the infected cells more effectively (26, 44) than it did the JEV-infected cells in this study. In order for JEV to achieve persistence, the infected cells must be able to adapt themselves to sustain virus replication without being lysed, and JEV itself may also need to change so the virus imposes no damage to its infected cells. Yet, the JEV released from the persistently infected B2-5 cells neither caused persistent infection nor generated truncated NS1 proteins upon a new round of primary infection in BHK-21 cells (data not shown), indicating that the virus itself is not sufficient to establish persistent infection. On the other hand, with the aid of bcl-2 expression, the surviving BHK-21 and CHO cells from the lytic infection phase appeared to have evolved a secure, as-yet-unclear ability to accommodate JEV persistence.

Emerging evidence suggests that the balance of genes in the bcl-2 family known to regulate the cell death pathway could be crucial for the establishment of alphavirus persistence (reviewed in reference 20;0). In addition to its antiapoptotic capability, Bcl-2 may also assist viruses to achieve persistence by blocking virus replication in the infected cells, as suggested by previous studies of Sindbis virus (51) and Semliki Forest virus (44). In contrast, our data revealed that the overexpression of bcl-2 did not appear to restrict JEV replication and spread during the primary infection in BHK-21 cells (Fig. 3). A similar phenomenon was also previously documented from a reovirus study (43). Conceivably, it is the antiapoptotic, rather than the antiviral, function of Bcl-2 that modulates the outcome of JEV infection progressing from the initial cytolytic phase toward the ultimate virus persistence. Intriguingly, however, the expression of bcl-2 has been proven unable to completely suppress JEV-induced cell death in either BHK-21 or CHO cells. Thus, exactly what renders some, but not all, of the bcl-2-expressing cells to become persistently infected by JEV remains elusive. One plausible mechanism, which is supported by the results derived from CHO-bcl2 cells (Fig. 4B), is that there is a cell population resistant to Bcl-2 cleavage being selected out during the JEV persistence process. In this scenario, slowdown of the turnover rate for Bcl-2 proteins may make the infected cells competent for developing JEV persistence. In fact, conversion of Bcl-2 to its BH4-domain-deleted protein has been attributed to the inability of Bcl-2 to block apoptotic cell death in some systems, whereas the caspase-cleavage-resistant constructs of Bcl-2 seemed to be more capable of preventing the cells from apoptotic attacks than the wild-type Bcl-2 (13). Nevertheless, it is unclear whether the resistance to Bcl-2 being proteolytically cut, as shown in Fig. 4B, was due to any mutation(s) occurring in bcl-2, caspase-3, or both. Whether the observed Bcl-2 cleavage-resistant phenotype was the cause or the effect of development of JEV persistence also needs to be investigated further. It should be noted that to unequivocally address this issue, an experiment employing a cell line expressing mutant Bcl-2 resistant to caspase cleavage (13) should be performed following JEV infection. Even more puzzling, in contrast to bcl-2, its close antiapoptotic homolog bcl-X_L failed to assist in development of JEV persistence in BHK-21 cells (Fig. 2A), indicating that only bcl-2 expression can give the cells a unique microenvironment suitable for the establishment of JEV persistence. What dictates such cellular difference by the two antiapoptotic effectors is of interest and needs to be explored in the future. It is conceivable that other cellular and viral gene products may also participate in the process of JEV persistence.

Characteristically, the truncated NS1 proteins were again observed in bcl-2-expressing cells persistently infected by JEV (Fig. 4 to 6); the biological properties of these NS1 proteins closely resembled the ones previously documented from the persistent murine neuroblastoma N18, as well as other persistent cells (11). This supports the notion that the aberrant NS1 expression is a molecular signature for JEV persistence in cultured cells (11). The alteration of virus structural gene products has been shown to be responsible for the persistent infections by several RNA viruses, including poliovirus (7), measles virus (4, 8), Sindbis virus (25), and lymphocytic choriomeningitis virus (35). However, in contrast to these viruses, JEV persistence was demonstrated to be intimately associated with its modified nonstructural protein NS1. While the precise role of NS1 in JEV persistence remains to be further explored, recent results from several studies implicate the involvement of NS1 in flavivirus RNA replication (15, 30, 31, 36, 37). In addition, flaviviral NS1 protein has also been suggested to play a role in virion maturation, a process which also utilizes the cellular secretory pathway (18, 32). These interpretations seem to account for our findings that nearly all of the persistent cells exhibited positive staining for viral antigens and yet less than 15% of them actually released viable virions in the infectious center assay. Conceivably, the generation of aberrant forms of NS1 proteins may reflect the reduction of viral replication and the subversion of virus-induced CPE during the establishment of JEV persistence. However, our data revealed that the stable expression of NS1 protein alone, regardless of whether truncated or full length, was incapable of influencing replication of the virus, which was thereby unable to persistently infect the engineered cells. Despite the close association with JEV persistence, the occurrence of aberrant NS1 proteins per se is insufficient for the creation of JEV persistence. This seems to imply that the generation of truncated NS1 (p39) proteins is merely an inevitable outcome of JEV persistence rather than a cause for its establishment in cultured cells. Since two forms of truncated NS1 proteins (p45 and p39), along with wild-type NS1 and NS1', coexist in B2-5/RP9 cells (Fig. 4 to 6), one may conjecture that homodimer p39-p39 and/or heterodimer p39-NS1 or p39-NS1' makes no contribution to the establishment of JEV persistence. Yet, the possible role of truncated NS1' (p45), homodimer p45-p45, and heterodimer p45-p39 or p45-NS1 in JEV persistence remains to be further investigated.

In summary, we have illustrated that the enforced expression of bcl-2 assisted JEV-infected cells to reach a critical balance point between virus replication and virus-induced cell death, thereby leading to a stable virus persistence state. Although there was no abrogation of virus replication and spread during the early cytolytic phase, bcl-2 overexpression appeared to allow some infected cells to be selected out during the persistence process. Together, the results here suggest that it is the antiapoptotic capability rather than the antiviral capability of bcl-2 that mediates the establishment of JEV persistence in cultured cells.